

Fig. 3. NR1 and CaMKII activation in the prefrontal cortex after the forced swimming test. Immediately after the forced swimming test, western blotting was performed in the prefrontal cortex (PFC) of saline- or phencyclidine (PCP)-treated mice (10 mg/kg/day s.c. for 14 days). Representative western blots and phospho-NR1/total-NR1 ($n = 4$ in each non-tested or tested group) (a) or phospho-CaMKII/total-CaMKII (b) ($n = 8$ in each non-tested or tested group) immunoactivity in the PFC. Values correspond to the mean ± S.E.M. Results with the one-way ANOVA were: (a) $F(3, 15) = 7.12$ ($p < 0.01$) and (b) $F(3, 31) = 2.95$ ($p < 0.01$). $^{**}p < 0.01$ vs. the saline-treated mice. (Bonferroni's test (a), (b)) Glu: glutamate. Test: forced swimming test group. Non-test: without forced swimming test group. Phosho-: P-, total-: T-.

3.4. Relationship between enhancement of immobility and CaMKII activation

To examine the relationship between the activation of CaMKII and enhancement of immobility in the forced swimming test, we evaluated the effect of a CaMKII inhibitor, KN93, on the immobility induced by forced swimming in mice. The mice microinjected with KN93 (10 nmol/site/bilaterally) into the PFC before the test showed a significantly prolonged immobility time, compared with the mice treated with vehicle or KN92, an inactive inhibitor (Fig. 4a). KN93, but not KN92, treatment significantly decreased the level of p-CaMKII expression after exposure to swim stress (Fig. 4b) without affecting locomotor activities. A significant inverse relationship between immobility time and phosphorylation of CaMKII in the PFC was observed in the forced swimming test (data not shown).

3.5. Effects of D-cycloserine, a partial agonist of the glycine recognition site at NMDA receptors, and DL-TBOA, a potent glutamate transporter inhibitor, on enhancement of immobility and impairment of CaMKII activation induced by PCP

When PCP-treated mice were injected with D-cycloserine (30 mg/kg s.c.) or DL-TBOA (10 nmol/site/bilaterally) 30 min before the test, the effects of PCP on immobility were significantly attenuated compared to those in the vehicle-treated group ($p < 0.05$; Fig. 5a and c). Both saline- and PCP-treated mice showed an increase in the amount of glutamate released in the PFC after DL-TBOA treatment (Fig. 5e). However, D-cycloserine and DL-TBOA did not affect the mobility in either saline- or PCP-treated mice. Further, D-cycloserine (30 mg/kg, s.c.) and DL-TBOA (10 nmol/site/bilaterally) did not affect the immobility of saline-treated mice [D-cycloserine: $F(2, 35) = 0.79$, $p = 0.23$; DL-TBOA: $F(2, 31) = 0.55$, $p = 0.58$] (Fig. 5a and c).

To confirm whether impairment of CaMKII activation is facilitated after D-cycloserine or DL-TBOA injection, we measured the p-CaMKII levels of the PFC in D-cycloserine- or DL-TBOA-injected, PCP-treated mice. The impairment of CaMKII activation in the PFC of PCP-treated mice was improved by D-cycloserine and DL-TBOA ($p < 0.05$, Fig. 5b and d). These results suggested that the impairment of NMDA–CaMKII signaling in the PFC, at least in part, is involved in the emotional deficits in PCP-treated mice. A significant inverse relationship between immobility time and the phosphorylation of CaMKII in the PFC was observed in the forced swimming test on both D-cycloserine and DL-TBOA treatment (data not shown).

4. Discussion

The repeated administration of NMDA receptor antagonists induces negative symptom-like emotional deficits in healthy volunteers or schizophrenia [17,33]. As previously reported, repeated, but not single, treatment with PCP elicits some negative symptom-like behavioral deficits (emotional deficits) such as impairments of social behavior in the social interaction test and an enhancement of immobility in the forced swimming test in mice [36–38,41]. The effect of PCP on the immobility appears to be sensitive to atypical antipsychotic (clozapine and resperidone) treatment, but not to haloperidol and tricyclic antidepressant treatments [36,37], which were consistent with the clinical findings that risperidone and clozapine, but not haloperidol and tricyclic antidepressants, improve negative symptoms in schizophrenia. Thus we have demonstrated that mice treated with PCP repeatedly provide a good animal model for emotional deficits relevant to negative symptoms of



Fig. 4. The effect of CaMKII inhibitors on immobility in the forced swimming test in naïve mice. The naïve mice were microinjected with vehicle, KN92, or KN93 (10 nmol/site/bilaterally) into the prefrontal cortex (PFC). (a) The immobility time was measured for 3 min, 30 min after the microinjection ($n = 11$ in each group non-swimming or swimming). (b) Representative western blots and phospho-CaMKII/total-CaMKII ($n = 5$ in each group) in the PFC of naïve mice. Values correspond to the mean ± S.E.M. Results with the one-way ANOVA were: (a) $F(2, 33) = 16.67$ ($p < 0.01$) and (b) $F(2, 15) = 4.85$ ($p < 0.05$). $^*p < 0.05$ vs. the vehicle-treated mice. (Bonferroni's test (a), (b)) Glu; glutamate, P/T-: phospho/total-.

schizophrenia. Abnormal prefrontal glutamatergic neurotransmission has also been described in PCP-treated mice, i.e. altered expression of the NMDA receptor subunit or an associated protein and decreased metabolic activity [7]. Our previous study has shown an imbalance of prefrontal serotonergic and dopaminergic functions in mice treated with PCP repeatedly after forced swimming, which may disrupt the regulation of glutamatergic transmission [38]. In the present study, we found a decreased level of extracellular glutamate and high K^+-induced glutamate release in the PFC of PCP-treated mice. These findings suggest that the abnormal glutamatergic transmission in the PFC induces the emotional deficits in the forced swimming test in PCP-treated mice.

One explanation for the decrease in extracellular glutamate release in the mice treated repeatedly with PCP is the enhanced function of glutamate transporters. There are reports suggesting the involvement of malfunctioning glutamate transporters in the etiology of schizophrenia [9,24,35]. Further, it has been indicated that there is an increase in the number of binding sites and protein levels of glutamate transporters in the PFC of postmortum tissue of schizophrenics [44]. In addition, some antipsychotics inhibit or down-regulate the function of glutamate transporters [29,45]. Our results showed an increased level of GLAST in the PFC of PCP-treated mice. Furthermore, the increase of GLAST expression is detected in the PFC but not in the nucleus accumbens (NAc) (data not shown). These results suggest that the regulation of GLAST expression is restricted in some brain regions. Taken together, it is suggested that the increase in GLAST expression is somewhat related to the decrease in extracellular glutamate release in the PFC. Although we failed to detect any change in GLT-1 expression in neither the PFC nor the NAc, it is possible that the function of GLT-1 is activated without a change in expression. A potent glutamate transporter blocker, DL-TBOA, attenuated the enhancement of immobility and increased the extracellular glutamate level in the PFC of PCP-treated mice. Therefore, these results suggest that, at least in part, the changes in levels of glutamate transporter in the PFC are related to the induction of emotional deficits in mice treated with PCP repeatedly. However, the precise mechanism is still unknown and further investigation is needed.

Low basal levels of extracellular glutamate and the impairment of glutamate release in the PFC may affect the post-synaptic glutamatergic signaling. We found that the mice treated with PCP repeatedly showed the decreased phosphorylation of NR1 and CaMKII after forced swimming, indicating an impairment of NMDA–CaMKII signaling. The NMDA receptor and CaMKII form a tight complex at the synapse, which may facilitate the activation of second messenger pathways [10,12,26]. CaMKII has been demonstrated to be required for regulating emotion and learning and memory in rodents [10,30]. Since CaMKII phosphorylation is caused not only via NMDA receptor but also other receptors, the relation of other receptors cannot be excluded. We have previously reported that the activation of extracellular signaling-regulated kinase (ERK) is not induced by exogenous NMDA, glycine, or spermidine in slices of the hippocampus and amygdala prepared from PCP-treated mice, suggesting abnormal ERK signaling via NMDA receptors in these mice [11]. Further, a blockade of CaMKII signaling caused by the bilateral microinjection of KN93, a CaMKII inhibitor, into the PFC of saline-treated mice induced an enhancement of immobility in the forced swimming test without affecting motor function. It is suggested that the low basal level of extracellular glutamate in the PFC is related to the impairment of post-synaptic signaling via NMDA receptors, which is supported by experiments with DL-TBOA and D-cycloserine. Namely, the elevation of the extracellular glutamate level by DL-TBOA and activation of NMDA receptors by D-cycloserine attenuated the enhancement of immobility and impairment of NR1–CaMKII signaling in mice treated with PCP repeatedly. Furthermore, we confirmed the inverse relationship between CaMKII phosphorylation in the PFC and immobility time in this experiment (data not shown). D-Cycloserine has been reported to be a candidate for a drug to treat schizophrenia [8,18]. As far as we know, this is the first report that abnormalities of pre-synaptic



Fig. 5. Effects of D-cycloserine and DL-TBOA on enhancement of immobility and impairment of CaMKII activation induced by phencyclidine. (a) The saline- or phencyclidine (PCP)-treated mice were administered D-cycloserine (3 and 30 mg/kg s.c.) 30 min before the measurement of immobility ($n = 12$–15). (c) The saline- or PCP-treated mice were microinjected with DL-TBOA (1 and 10 nmol/bilaterally) into the PFC 10 min before the measurement of immobility ($n = 14$–20). Representative western blots and phospho-CaMKII/total-CaMKII immunoreactivity after D-cycloserine (b) and DL-TBOA (d) treatment in the PFC of PCP-treated mice ($n = 5$–7). (e) DL-TBOA-induced glutamate release in the PFC of saline- and PCP-treated mice. Fractions were collected for 40 min. Basal extracellular glutamate levels were: vehicle-injected saline-treated mice, 4.68 ± 2.80 pmol ($n = 4$); vehicle-injected PCP-treated mice, 0.83 ± 0.51 pmol ($n = 3$). Values correspond to the mean ± S.E.M. Results with the one-way ANOVA were: (a) $F(2, 41) = 7.92$ ($p < 0.01$); (b) $F(2, 15) = 3.998$ ($p < 0.05$); (c) $F(2, 53) = 4.98$ ($p < 0.05$); (d) $F(2, 19) = 5.515$ ($p < 0.05$). $^*p < 0.05$ vs. the vehicle-treated mice (Bonferroni's test (a)–(d) or Student's t-test (e)). DCS: D-cycloserine and Glu: glutamate. Test: forced swimming test group. Non-test: without forced swimming test group. P/T-: phospho/total-.

glutamatergic transmission and post-synaptic NMDA–CaMKII signaling are induced by repeated PCP treatment and are involved in the enhancement of immobility (emotional deficit) in the PCP-treated mice.

We found cell shrinkage and glial activation without cell death and activated s100-positive cells in the PFC after repeated PCP treatment. It has been reported that acute injection of PCP causes the increased release of glutamate in the PFC [2]. Increases in the extracellular synaptic glutamate concentration to excitotoxic levels lead to neuronal damage [5,6]. However, we could not detect apoptosis or a decrease in cell number, although the PCP-treated mice showed a decrease in cell size in the PFC as previously reported: NMDA antagonists induce not cell death but vacuolation if the severe NMDA receptor hypofunction is relatively brief [39,40]. Usually, reactive gliosis occurs after injury to the CNS [43]. In the present study, glial activation was observed with a decrease of neuronal cell size in the PFC of PCP-treated mice. Taken together with the previous reports that subchronic PCP treatment decreases the number of dendritic spine synapses in the rat PFC with astrogliosis [16], one explanation for the glial activation is that neuronal damage was occurred after repeated PCP treatment. S100, a calcium-binding protein, is expressed in astrocytes at high levels in brain lesions and used as a marker for identifying astrocytes especially in the damaged CNS [43]. Other reports have also indicated that chronic treatment with PCP activates astrocytes and damages neurons [20,23,46]. Although we did not examine the relation between glial activation and GLAST's up-regulation, glial function might

have changed during the PCP treatment. Further investigation is needed to elucidate the mechanism of activation of glia with the up-regulation of GLAST expression. Our results clearly suggest that repeated PCP treatment disrupts the pre-synaptic glutamatergic transmission and activation of CaMKII mediated via NMDA receptors.

In conclusion, our results suggest that activation of glia and up-regulation of glial transporters occurred following the neuronal damage caused by treatment with PCP for 14 days. We emphasize that this leads to altered glutamatergic functions via NMDA receptors involving pre-synaptic dysfunction in the PFC and induces emotional deficits in PCP-treated mice. Thus, PCP-treated mice are considered to be a good model with which to evaluate negative symptom-like emotional deficits and these results may support the hypothesis of glutamatergic hypofunction in schizophrenia. The study of PCP-treated mice should help us to develop medications for negative symptoms of schizophrenia.

Acknowledgements

This work was supported, in part, by grants-in-aid for scientific research from the Japan Society for the Promotion of Science (14370031, 15922139, 16922036, and 17390018), for Scientific Research on Priority Areas on "elucidation of glia–neuron network mediated information processing systems" from the Ministry of Education, Culture, Sports, Science and Technology (16047214), from the Research on Regulatory Science of Pharmaceuticals and Medical Devices, from a Funds from Integrated Molecular Medicine for Neuronal and Neoplastic Disorders (21st Century COE program), from the Japan Brain Foundation, from the Mitsubishi Pharma Research Foundation, and from an SRF Grant for Biomedical Research.

References

[1] Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978;135:1081–4.
[2] Adams B, Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 1998;18:5545–54.
[3] Carlsson A, Hansson LO, Waters N, Carlsson ML. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 1997;61:75–94 [review].
[4] Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia—therapeutic implications. Biol Psychiatry 1999;46:1388–95 [review].
[5] Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623–34 [review].
[6] Choi DW. Neurodegeneration: cellular defences destroyed. Nature 2005;433:696–8.
[7] Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 2003;28:265–75.
[8] Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci 2003;1003:318–27 [review].
[9] Danbolt NC. Glutamate uptake. Prog Neurobiol 2001;65:1–105.
[10] Du J, Szabo ST, Gray NA, Manji HK. Focus on CaMKII: a molecular switch in the pathophysiology and treatment of mood and anxiety disorders. Int J Neuropsychopharmacol 2004;7:243–8 [review].
[11] Enomoto T, Noda Y, Mouri A, Shin EJ, Wang D, Murai R, et al. Long-lasting impairment of associative learning is correlated with a dysfunction of *N*-methyl-D-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol 2005;68:1765–74.
[12] Fink CC, Meyer T. Molecular mechanisms of CaMKII activation in neuronal plasticity. Curr Opin Neurobiol 2002;12:293–9.
[13] Frankle WG, Lerma J, Laruelle M. The synaptic hypothesis of schizophrenia. Neuron 2002;39:205–16.
[14] Franklin JBJ, Paxinos GT. The mouse brain. In: Stereotaxic coordinates. New York: Academic; 1997.
[15] Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trend Neurosci 2001;24:527–33.
[16] Hajszan T, Leranth C, Roth RH. Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol Psychiatry 2006;6:639–44.
[17] Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301–8.
[18] Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9:984–97 [review].
[19] Jentsch JD, Redmond Jr DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997;277:953–5.
[20] Jebelli AK, Doan N, Ellison G. Prenatal phencyclidine induces heightened neurodegeneration in rats in some brain regions, especially during 2nd trimester, but possible anti-apoptotic effects in others. Pharmacol Toxicol 2002;90:20–5.
[21] Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999;20:201–25 [review].
[22] Jentsch JD, Tran A, Le D, Youngren KD, Roth RH. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 1997;17:92–9.
[23] Johnson KM, Phillips M, Wang C, Kevetter GA. Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex. J Neurosci Res 1998;52:709–22.
[24] Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980;20:379–82.
[25] Lerner SE, Burns RS. Legal issues associated with PCP abuse—the role of the forensic expert. NIDA Res Monogr 1986;64:229–36.
[26] Leonard AS, Lim IA, Hemsworth DE, Horne MC, Hell JW. Calcium/calmodulin-dependent protein kinase II is associated with the *N*-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1999;96:3239–44.
[27] Maddox VH, Godefroi EF, Parcell RF. The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem 1965;56:230–5.
[28] Mandillo S, Rinaldi A, Oliverio A, Mele A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 2003;14:533–44.
[29] Melone M, Vitellaro-Zuccarello L, Vallejo-Illarramendi A, Perez-Samartin A, Matute C, Cozzi A, et al. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol Psychiatry 2001;6:380–6.
[30] Miller S, Yasuda M, Coats JK, Jones Y, Martone ME, Mayford M. Disruption of dendritic translation of CaMKII alpha impairs stabilization of synaptic plasticity and memory consolidation. Neuron 2002;36:507–19.
[31] Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J Neurosci 2001;21:750–7.
[32] Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999;98:427–36.
[33] Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modeling schizophrenia. Curr Opin Pharmacol 2005;5:101–6.

[34] Nagai T, Yamada K, Yoshimura M, Ishikawa K, Miyamoto Y, Hashimoto K, et al. The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci USA 2004;101:3650–5.
[35] Nanitsos EK, Nguyen KT, St'astny F, Balcar VJ. Glutamatergic hypothesis of schizophrenia: involvement of Na^+/K^+-dependent glutamate transport. J Biomed Sci 2005;12:975–84.
[36] Noda Y, Yamada K, Furukawa H, Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 1995;116:2531–7.
[37] Noda Y, Mamiya T, Furukawa H, Nabeshima T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 1997;324:135–40.
[38] Noda Y, Kamei H, Mamiya T, Furukawa H, Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 2000;23:375–87.
[39] Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991;254:1515–8.
[40] Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999;33:523–33 [review].
[41] Qiao H, Noda Y, Kamei H, Nagai T, Furukawa H, Miura H, et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 2001;12:11–5.
[42] Rainey Jr JM, Crowder MK. Prolonged psychosis attributed to phencyclidine: report of three cases. Am J Psychiatry 1975;132:1076–8.
[43] Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 1997;20:570–7 [review].
[44] Simpson MD, Slater P, Deakin JF. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia. Biol Psychiatry 1998;44:423–7.
[45] Vallejo-Illarramendi A, Torres-Ramos M, Melone M, Conti F, Matute C. Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia 2005;50:276–9.
[46] Wang C, Showalter VM, Hillman GR, Johnson KM. Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat forebrain. J Neurosci Res 1999;55:762–9.

An Inducer for Glial Cell Line-Derived Neurotrophic Factor and Tumor Necrosis Factor–α Protects Against Methamphetamine-Induced Rewarding Effects and Sensitization

Minae Niwa, Atsumi Nitta, Yuichiro Yamada, Akira Nakajima, Kuniaki Saito, Mitsuru Seishima, Liya Shen, Yukihiro Noda, Shoei Furukawa, and Toshitaka Nabeshima

Background: There are few efficacious medications for drug dependence. We investigated the potential of Leu-Ile, which induces the expression of glial cell line-derived neurotrophic factor (GDNF) and tumor necrosis factor-α (TNF-α), as a novel therapeutic agent for methamphetamine (METH)-induced dependence.

Methods: The levels of GDNF and TNF-α messenger RNA (mRNA) were determined by real-time reverse transcription polymerase chain reaction. Enzyme immunoassays and immunohistochemistry were employed to determine levels of these proteins. Effects of Leu-Ile on METH-induced rewarding effects and sensitization were investigated with conditioned place preference and locomotor activity tests. Extracellular dopamine (DA) levels and DA uptake into synaptosomes were examined with an in vivo microdialysis and trititated thymidine ([^{3}H]) DA uptake assay.

Results: Leu-Ile induced the expression of not only GDNF but also TNF-α. Pretreatment with Leu-Ile blocked the acquisition of METH-induced place preference and sensitization. Interestingly, post-treatment with Leu-Ile attenuated them even after their development. An inhibitory effect of Leu-Ile on METH-induced place preference was observed in neither GDNF heterozygous nor TNF-α knockout mice. Leu-Ile inhibited DA release in the nucleus accumbens and the decrease in synaptosomal DA uptake in the midbrain induced by repeated METH treatment.

Conclusions: These results suggest that Leu-Ile inhibits METH-induced rewarding effects and sensitization by regulating extracellular DA levels via the induction of GDNF and TNF-α expression.

Key Words: Dopamine (DA), glial cell line-derived neurotrophic factor (GDNF), methamphetamine (METH), rewarding effects, sensitization, tumor necrosis factor-α (TNF-α)

The abuse of substances such as psychostimulants, opiates, nicotine, and alcohol has become a significant social and public health concern worldwide. Activation of the mesocorticolimbic dopamine (DA) system has been implicated in the positive reinforcing (rewarding) effects of drugs of abuse (Robbins and Everitt 1999; Yamada and Nabeshima 2004). The psychostimulant effects of methamphetamine (METH), a typical drug of abuse, are associated with an increase in extracellular DA levels in the brain, by facilitating the release of DA from presynaptic nerve terminals and inhibiting reuptake (Giros *et al.* 1996; Heikkila *et al.* 1975; Seiden *et al.* 1993).

Neurotropic factors and cytokines, which are known to influence synaptic transmission and neuronal morphology (Boulanger and Poo 1999; Connor and Dragunow 1998; Neumann *et al.* 2002), might be involved in alterations of the morphology of dendrites and dendritic spines in the nucleus accumbens (NAc) and prefrontal cortex after repeated injection of psychostimulants (Robinson and Kolb 1997, 1999; Yamada *et al.* 2000). Glial cell line-derived neurotrophic factor (GDNF) inhibits the cocaine-induced upregulation of tyrosine hydroxylase activity in the ventral tegmental area (VTA) and blocks behavioral responses to cocaine (Messer *et al.* 2000). Furthermore, we have previously demonstrated that tumor necrosis factor-α (TNF-α) inhibits METH-induced dependence (Nakajima *et al.* 2004; Yamada and Nabeshima 2004). Taken together, GDNF and TNF-α would be candidates for therapeutic agents against drug dependence. However, there are serious obstacles to their therapeutic application: it is difficult to deliver GDNF from the periphery to the brain, because it is a macromolecule that cannot penetrate the blood-brain barrier (BBB) (Lin *et al.* 1993) and is easily broken down by proteases in the blood stream. In addition, TNF-α, an inflammatory cytokine, damages the peripheral tissues, because it triggers the expression of other cytokines (Bluthe *et al.* 1994). Therefore, GDNF and TNF-α cannot be used directly as therapeutic tools for drug dependence. We hypothesized that a low-molecular-weight compound that induces production of GDNF and TNF-α in the brain could be a novel therapeutic agent for drug dependence. Previous study has demonstrated that inflammatory stimuli such as TNF-α and lipopolysaccharide induces the synthesis of GDNF in cultured astrocytes from mouse brain (Appel *et al.* 1997). Furthermore, Leu-Ile, a hydrophobic dipeptide, induces GDNF synthesis both in vivo and in vitro (Nitta *et al.* 2004). Taken together, Leu-Ile is expected to induce the production of not only GDNF but also TNF-α and to inhibit drug dependence.

From the Department of Neuropsychopharmacology and Hospital Pharmacy (MN, AN, YY, AN, YN, TN), Nagoya University Graduate School of Medicine; Division of Clinical Science in Clinical Pharmacy Practice (YN), Management and Research, Faculty of Pharmacy, Meijo University, Nagoya, Japan; Department of Informative Clinical Medicine (KS, MS), Gifu University Graduate School of Medicine; Laboratory of Molecular Biology (SF), Gifu Pharmaceutical University, Gifu, Japan; and Laboratory of Cellular Carcinogenesis and Tumor Promotion (LS), Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Address reprint requests to Toshitaka Nabeshima, Ph.D., Nagoya University Graduate School of Medicine, Department of Neuropsychopharmacology and Hospital Pharmacy, Tsurumai-cho 65, Showa-ku Nagoya 466-8560, Japan; E-mail: tnabeshi@med.nagoya-u.ac.jp.

Received February 28, 2006; revised June 9, 2006; accepted June 12, 2006.

0006-3223/07/$32.00
doi:10.1016/j.biopsych.2006.06.016

BIOL PSYCHIATRY 2007;61:890–901

In the present study, we examined: 1) whether Leu-Ile induces production of TNF-α, and 2) the effects of Leu-Ile on the rewarding actions and the sensitization to the locomotor-stimulating effects of METH and on the increase in extracellular DA levels and the decrease in DA uptake induced by METH.

Methods and Materials

Reagents

Glial cell line-derived neurotrophic factor and TNF-α were donated by Amgen (Thousand Oaks, California) and Dainippon Pharmaceutical (Osaka, Japan), respectively. Leu-Ile was purchased from Kokusan Chemical (Tokyo, Japan). All other materials used were of reagent grade.

Animals

Animals were housed in plastic cages and kept in a temperature-, humidity-, and light-controlled room (23° ± 1°C; 50% ± 5% humidity; 12-hour light/dark cycle starting at 8:00 AM) and had ad libitum access to food and water, except during behavioral experiments. Animal care and use was in accordance with the Principles of Laboratory Animal Care (National Institutes of Health Publication 85-123, 1983) and was approved by the Institutional Animal Care and Use Committee of Nagoya University School of Medicine. Animals were treated according to the Guidelines of Experimental Animal Care issued from the Office of the Prime Minister of Japan. The behavioral experiment's schedule is shown in Figure 1.

The wild-type C57BL/6 mice were obtained from Slc Japan (Hamamatsu, Japan).

Male C57BL/6-GDNF heterozygous [GDNF-(±)] mice and C57BL/6-TNF-α knockout (TNF-α-[−/−]) mice, 8–12 weeks of age, were used in the experiments. The GDNF-(±) and TNF-α-(−/−) mice were generated as described previously (Nakajima *et al.* 2004; Pichel *et al.* 1996; Taniguchi *et al.* 1997); GDNF (−/−) homozygous knockout mice die shortly after birth (postnatal 7 days), but GDNF (±) mice are viable. Glial cell line-derived neurotrophic factor levels in the frontal cortex (Fc), NAc, striatum, and hippocampus (Hip) of GDNF-(±) mice are 54.8%, 65.4%, 59.0%, and 66.8 %, respectively, of those in littermate GDNF-(+/+) mice (Table 1). Littermate GDNF-(+/+) mice were used as control subjects in the behavioral experiments.

Drug Treatment

Mice were administered Leu-Ile (1.5 and 15 μmol/kg, IP) once/day 1 hour before METH (1 mg/kg, SC) treatment for 9 days. In the withdrawal experiment, mice were administered Leu-Ile or vehicle for 5 days after the withdrawal from METH after 9 successive days of METH administration. To determine trititated thymidine ([^{3}H]) DA uptake, messenger RNA (mRNA) expression, and protein levels, mice were decapitated 1, 2, and 24 hours after the last METH injection, respectively.

Enzyme Immunoassay of GDNF

Glial cell line-derived neurotrophic factor levels were measured with an enzyme immunoassay (EIA) with a minor modification (Nitta *et al.* 1999a, 1999b, 2004). Homogenate buffer (.1 mol/L Tris-HCl [pH 7.4] containing 1 mol/L sodium chloride (NaCl), 2% bovine serum albumin, 2 mmol/L ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA), and .2% sodium nitride [Na3N]) was added to brain tissue at a ratio of 1 g wet weight / 19 mL of buffer, pulse-sonicated for 100 sec, and centrifuged at 100,000 *g* for 30 min. The supernatant was collected and used for the EIA.



Figure 1. Experimental schedules. **(A)** Experimental schedule for the conditioned place preference task. Mice were co-treated with Leu-Ile and methamphetamine (METH) in the conditioning period. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) 1 hour before receiving METH (1 mg/kg, SC) or saline. Closed arrows indicate the days of METH or saline injection. **(B)** Experimental schedule for the conditioned place preference task to investigate the effects of Leu-Ile after the withdrawal from METH. Mice were not treated with Leu-Ile in the conditioning period. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) for 5 days after withdrawal from METH. **(C)** Experimental schedule for measurement of locomotor activity. Mice were treated with Leu-Ile during the habituation period for 3 days and then co-treated with Leu-Ile and METH for 9 days. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) 1 hour before the METH (1 mg/kg, SC) injection. Locomotor activity was measured for 2 hours after the METH treatment. Open arrows indicate the days when locomotor activity was measured. **(D)** Experimental schedule for measurement of locomotor activity to investigate the effects of Leu-Ile after the withdrawal from METH. Mice were treated with Leu-Ile after the establishment of METH (1 mg/kg, SC)-induced sensitization: mice were treated with METH for 9 days and then with Leu-Ile (1.5 and 15 μmol/kg, IP) for 5 days without METH. On day 18, mice were administered only METH (1 mg/kg, SC), and locomotor activity was measured for 2 hours after the METH treatment.

Semi-Quantative mRNA Analysis by Real-Time Reverse Transcription Polymerase Chain Reaction

Corti-hippocampal neurons from 18-day-old rat embryos were cultured as previously described (Nitta *et al.* 1999a, 1999b). More than 95% of the cells were positive for microtuble-associated protein-2 (MAP2) immunoreactivity. Corti-hippocampal neurons of 18-day-old rat embryos were cultured in serum-free

Table 1. The Difference of GDNF Levels in the Brain (Fc, NAc, Str, Hip) Between GDNF-(+/+) and GDNF-(+/−) Mice

Brain Region	GDNF Levels (pg/g Wet Tissue)		
	GDNF-(+/+) Mice	GDNF-(+/−) Mice	% of GDNF-(+/+) Mice
Fc	1285.0 ± 254.3	704.0 ± 26.4*	54.8
NAc	1253.4 ± 58.5	820.2 ± 58.4*	65.4
Str	2083.1 ± 231.0	1229.4 ± 178.2*	59.0
Hip	782.2 ± 99.9	522.5 ± 20.9*	66.8

Mice were decapitated without any treatment, and the brains were quickly removed. Glial cell line-derived neurotrophic factor (GDNF) levels were measured using an enzyme immunoassay. Values are means ± SE ($n = 10$).

Fc, frontal cortex; Hip, hippocampus; NAc, nucleus accumbens; Str, striatum.

*$p < .05$ versus GDNF-(+/+) mice.

defined medium containing Leu-Ile (.037, .37, 3.7, and 37 μg/mL) or TNF-α (2, 20, 100, and 200 ng/mL). Total RNA was isolated with an RNeasy Mini Kit (Qiagen, Hilden, Germany) and converted into complementary DNA with a SuperScriptTM First-Strand System for RT-PCR Kit (Invitrogen Life Technologies, Carlsbad, California). The rat GDNF primers used were as follows: 5'-AGCTGCCAGCCCAGAGAATT-3' (forward) and 5'-GCACCCCCGATTTTTGC-3' (reverse), and TaqMan probe: 5'-CAGAGGGAAAGGTCGCAGAGGCC-3'. The rat TNF-α primers used were as follows: 5'-ATTTGGCCCCATCCTTCC-3' (forward) and 5'-GCCTCCATGGCAGAGCC-3' (reverse), and TaqMan probe: 5'-TCCCAGGACATCAGGACTCTGTTCCC-3'. The 18S ribosomal RNA Kit was used as the internal control (PE Applied Biosystems, Foster, California). The amplification consisted of an initial step (50°C for 2 min and 95°C for 2 min) and then 40 cycles of denaturation for 15 sec at 95°C and annealing for 1 min at 60°C in an iCycle iQ Detection System (Bio-Rad Laboratories, Tokyo, Japan). The expression levels were calculated as described previously (Wada *et al.* 2000).

Immunohistochemical Analysis

Polyclonal rabbit anti-GDNF (1:50; sc-328; Santa Cruz Biotechnology, Santa Cruz, California), polyclonal goat anti-TNF-α (1:100; R&D Systems, Minneapolis, Minnesota), monoclonal mouse anti-MAP2 (1:200; Sigma-Aldrich, Saint Louis, Missouri), and monoclonal mouse anti-glial fibrillary acidic protein (GFAP) antibody (1:200, Chemicon International, Temecula, California) served as primary antibodies. Goat anti-rabbit Alexa Fluor 546 (1:1000, Molecular Probes, Eugene, Oregon) and goat anti-mouse Alexa Fluor 488 (1:1000, Molecular Probes) served as secondary antibodies for GDNF immunostaining. Donkey anti-goat Alexa Fluor 546 (1:1000, Molecular Probes) and rabbit anti-mouse Alexa Fluor 488 (1:1000, Molecular Probes) served as secondary antibodies for TNF-α immunostaining. Each stained tissue was observed under a fluorescence microscope (Axioskoop 2 plus: Carl Zeiss, Jena, Germany) and analyzed with Axiovision 3.0 systems (Carl Zeiss). The area with TNF-α-positive cells in the defined NAc region of mice was determined with the software WinROOF (Mitani, Fukui, Japan) (Kuwahara *et al.* 1999; Tsuji *et al.* 1999). We employed an immunostaining method with which one can analyze the distribution and levels of TNF-α protein in the present investigation, because it is too difficult to use Western blotting or an enzyme immunoassay to quantify the amount of TNF-α protein in brain tissue.

Measurement of the TNF-α Concentration in Peripheral Blood

Blood was collected into tubes containing 5% EDTA 1, 2, and 4 hours after the injection of TNF-α (4 μg/body, IP). Mice were treated with Leu-Ile (1.5 μmol/kg, IP), and their blood was collected into tubes containing 5% EDTA 0, 1, 2, 4, and 8 hours after the injection. The blood samples were centrifuged at 2000 × *g* for 20 min at 4°C. The supernatants were taken as the samples. The TNF-α concentration was assessed by using a specific human (QuantiGlo QTA00, R&D Systems) or mouse TNF-α enzyme-linked immunosorbent assay (ELISA) kit (Quantikine MTA00, R&D Systems), according to the instructions provided.

Behavioral Tests

Conditioned Place Preference. The place conditioning paradigm was performed by using previously established procedure with a minor modification (Nagai *et al.* 2004; Nakajima *et al.* 2004; Noda *et al.* 1998). The experimental schedule for the conditioned place preference (CPP) task is shown in Figures 1A and 1B. The mouse was allowed to move freely between transparent and black boxes for 15 min once/day for 3 days (days 1–3) in the preconditioning. On day 3, the time the mouse spent in each box was measured. On days 4, 6, and 8, the mouse was treated with METH and confined in either the transparent or black box for 20 min. On days 5, 7, and 9, the mouse was given saline and placed opposite the METH-conditioning box for 20 min. On day 10, the postconditioning test was performed without drug treatment, and the time the mouse spent in each box was measured for 15 min.

Locomotor Activity. Locomotor activity was measured with an infrared detector (Neuroscience, Tokyo, Japan) in a plastic box (32 × 22 × 15 cm high). Mice were administered METH (1 mg/kg, SC) or saline 1 hour after the Leu-Ile treatment, and the locomotor activity was measured for 2 hours immediately after the METH or saline administration (Figure 1C). In the withdrawal experiment, mice were administered Leu-Ile or vehicle for 5 days after the withdrawal from METH (days 13–17) after 9 successive days of METH administration. On day 18, the mice were administered only METH (1 mg/kg, SC), and locomotor activity was measured for 2 hours immediately after the administration (Figure 1D).

In Vivo Microdialysis

Mice were anesthetized with sodium pentobarbital, and a guide cannula (AG-8, EICOM, Kyoto, Japan) was implanted into the NAc (+1.1 mm anteroposterior, +1.0 mm mediolateral from bregma, and −4.0 mm dorsoventral to dura) according to the atlas of Franklin and Paxinos (1997) and secured to the skull with stainless steel screws and dental acrylic cement. One day after the operation, a dialysis probe (AI-8-1; 1-mm membrane length, EICOM) was inserted through the guide cannula and perfused continuously with artificial cerebrospinal fluid (aCSF; 147 mmol/L NaCl, 4 mmol/L potassium chloride, and 2.3 mmol/L calcium dichloride) at a rate of 1.0 μL/min. Dialysate was collected in 20-min fractions and injected into the HPLC system (EICOM) for the measurement of DA levels. Three samples were used to establish baseline levels of extracellular DA before the administration of Leu-Ile and METH.

Synaptosomal [^{3}H] DA Uptake

Midbrain synaptosomal [^{3}H] DA uptake was determined as previously described (Fleckenstein *et al.* 1997; Nakajima *et al.* 2004). Samples were incubated at 37°C for 4 min, and then ice-cold Krebs-Ringer's solution containing 10 μmol/L GBR12909, a specific DA uptake inhibitor, was added. Nonspecific values were determined in the presence of 100 μmol/L GBR12909. The radioactivity trapped on Whatman GF/B filters (Brandel, Gaith-

ersburg, Maryland) was measured with a liquid scintillation counter.

Statistical Analysis

All data were expressed as means ± SEM. Statistical differences between two groups were determined with Student *t* test. Statistical differences among more than three groups were determined with a one-way analysis of variance (ANOVA) or a repeated ANOVA followed by the Bonferroni multiple comparison test; $p < .05$ was regarded as statistically significant.

Results

Effect of Leu-Ile on METH-Induced Increase in GDNF Levels

Levels of GDNF expression induced by Leu-Ile (.037, .37, 3.7, and 37 μg/mL) were determined in the cultured neurons with the EIA method. The GDNF levels were significantly increased 24 hours after the addition of Leu-Ile (.37 μg/mL) resulting in a bell-shaped dose response curve compared with the control group [$F(4,25) = 8.895$, $p < .05$, one-way ANOVA] (Figure 2A). Therefore, a dose of .37 μg/mL was used in this experiment. The time course of GDNF mRNA expression was determined 6, 12, and 24 hours after Leu-Ile (.37 μg/mL) treatment in the cultured neurons. The GDNF mRNA levels were significantly elevated 24 hours after Leu-Ile treatment in the cultured neurons compared with the control group [$F(5,42) = 7.627$, $p < .05$, one-way ANOVA] (Figure 2B).

Glial cell line-derived neurotrophic factor–positive cells were found among the neurons, which were immunopositive for MAP2, in the NAc of mice co-treated with Leu-Ile (1.5 μmol/kg, IP) and METH (1 mg/kg, SC); GDNF-positive cells were also found among astro glial cells, which were immunopositive for GFAP, in the NAc of mice co-treated with Leu-Ile (1.5 μmol/kg, IP) and METH (1 mg/kg, SC) (Figure 2C).

The GDNF levels in the NAc were determined after the co-administration of Leu-Ile and METH with the EIA method. Methamphetamine (1 mg/kg) increased GDNF levels in the NAc compared with those in the vehicle/saline-treated mice. The GDNF levels after the co-administration of Leu-Ile (1.5 and 15 μmol/kg, IP) and METH (1 mg/kg) were much more increased compared with those in the vehicle/METH-treated mice [$F(5,38) = 16.971$, $p < .05$, one-way ANOVA] (Figures 2C and 2D). Moreover, we determined GDNF levels in the NAc after Leu-Ile treatment during the withdrawal from METH after 9 successive days of METH administration. The schedule is described in Figure 1D. An acute challenge of METH in mice treated with vehicle for 5 days after the development of METH-induced sensitization increased GDNF levels in the NAc compared with levels in the saline/vehicle/METH-treated mice. An acute challenge of METH in mice treated with Leu-Ile (1.5 and 15 μmol/kg) for 5 days after the development of METH-induced sensitization resulted in a much greater increase compared with levels in the METH/vehicle/METH-treated mice [$F(3,20) = 23.777$, $p < .05$, one-way ANOVA] (Figure 2E).

Effect of Leu-Ile on METH-Induced Increase in TNF-α Levels

Expression levels of TNF-α mRNA induced by Leu-Ile (.037, .37, 3.7, and 37 μg/mL) were determined in the cultured neurons with the real-time reverse transcription polymerase chain reaction (RT-PCR) method, because TNF-α induces the synthesis of GDNF as described in the introductory section of this report. Levels of TNF-α mRNA were significantly increased 24 hours after the addition of Leu-Ile (.37 μg/mL), resulting in a bell-shaped dose response curve compared with the control group [$F(4,30) = 2.572$, $p < .05$, one-way ANOVA] (Figure 3A). The time course of TNF-α mRNA expression was determined 6, 12, and 24 hours after Leu-Ile (.37 μg/mL) treatment in the cultured neurons. The TNF-α mRNA levels were significantly elevated 24 hours after the Leu-Ile (.37 μg/mL) treatment in the cultured neurons compared with the control group [$F(5,42) = 6.067$, $p < .05$, one-way ANOVA] (Figure 3B).

Tumor necrosis factor-α–positive cells were found among the neurons that were immunopositive for MAP2 but not for GFAP in the NAc of mice co-treated with Leu-Ile (1.5 μmol/kg, IP) and METH (1 mg/kg, SC) (Figure 3C).

The areas occupied by TNF-α-immunopositive cells were measured to estimate the effects of Leu-Ile on the production of TNF-α protein. The area with TNF-α immunoreactive cells was determined in the NAc by using the software WinROOF (Mitani Shoji, Fukui, Japan). Methamphetamine (1 mg/kg, SC) potentiated the immunoreactivity to TNF-α in the NAc. After the co-administration of Leu-Ile (1.5 and 15 μmol/kg, IP) and METH (1 mg/kg, SC), immunoreactivity was much more increased in the NAc [$F(5,32) = 26.836$, $p < .05$, one-way ANOVA] (Figures 3C and 3D). Moreover, we determined levels of TNF-α protein in the NAc after Leu-Ile treatment during the withdrawal from METH after 9 successive days of METH administration. The schedule is described in Figure 1D. An acute challenge of METH in mice treated with vehicle for 5 days after the development of METH-induced sensitization increased TNF-α levels in the NAc compared with those in the saline/vehicle/METH-treated mice. An acute challenge of METH in mice treated with Leu-Ile (1.5 and 15 μmol/kg) for 5 days after the development of METH-induced sensitization markedly increased TNF-α levels compared with those in the METH/vehicle/METH-treated mice [$F(3,22) = 26.800$, $p < .05$, one-way ANOVA] (Figure 3E).

We checked whether the concentration of TNF-α in venous blood was changed after the intraperitoneal injection of Leu-Ile in mice. In venous blood, the TNF-α concentration was not changed 1, 2, 4, and 8 hours after the Leu-Ile treatment (1.5 μmol/kg, IP). In contrast, the concentration was dramatically increased 1, 2, and 4 hours after the TNF-α treatment (4 μg/body, IP) (Figure 3F).

Regulatory Effect of TNF-α on GDNF Expression in Cultured Neurons

With the real-time RT-PCR method, levels of GDNF mRNA stimulated by TNF-α (20 and 100 ng/mL) were determined in the cultured neurons. The mRNA levels were significantly elevated by TNF-α (100 ng/mL) compared with the control group [$F(2,11) = 7.826$, $p < .05$, one-way ANOVA] (Figure 4A). Next, the time course of GDNF mRNA expression was determined 6, 12, and 24 hours after TNF-α (100 ng/mL) treatment. The mRNA levels were significantly elevated 24 hours after the treatment with TNF-α (100 ng/mL) compared with the control group [$F(5,46) = 6.114$, $p < .05$, one-way ANOVA] (Figure 4B). The GDNF levels showed a significant increase 24 hours after the addition of TNF-α (100 and 200 ng/mL) compared with the control group [$F(4,25) = 12.372$, $p < .05$, one-way ANOVA] (Figure 4C).

Effects of Leu-Ile on METH-Induced Place Preference and Hyperlocomotion/Sensitization in Wild-Type Mice

We investigated the effects of Leu-Ile on the behavioral responses to METH. First, the effects of Leu-Ile on the rewarding effects of METH were examined in CPP paradigm, in which animals learn the association of an environment paired with drug

exposure; CPP is, therefore, considered a measure of the rewarding properties of drugs of abuse. The experimental schedule is described in Figure 1A. As shown in Figure 5A, METH (1 mg/kg, SC) produced place preference in mice. When mice were treated with Leu-Ile (1.5 μmol/kg, IP) 1 hour before receiving METH, the METH-induced place preference was significantly attenuated [$F(5,53) = 5.338$, $p < .05$, one-way ANOVA] (Figure 5A). Leu-Ile (1.5 and 15 μmol/kg, IP) itself failed to induce place preference in mice (Figure 5A second and third columns in saline-treated group).

We next examined the effects of Leu-Ile on METH-induced hyperlocomotion and sensitization. The sensitization to the locomotor-stimulating effects is argued to reflect one neuroadaptive process associated with dependence. The experimental schedule is described in Figure 1C. As shown in Figure 5B, acute METH treatment at a dose of 1 mg/kg caused a marked increase in locomotor activity, and repeated administration for 9 days resulted in an enhancement of the locomotor-stimulating effect of METH (sensitization) [$F(4,45)=2.919$, $p < .05$, one-way ANOVA]. Leu-Ile (1.5 and 15 μmol/kg, IP) did not inhibit acute METH-induced hyperlocomotion on day 4, although it inhibited METH-induced hyperlocomotion and sensitization on days 8–12 [$F(5,54) = 24.374$ at day 8, $F(5,54) = 20.738$ at day 10, $F(5,54) = 30.956$ at day 12, $p < .05$, one-way ANOVA] (Figure 5B). Leu-Ile (1.5 and 15 μmol/kg, IP) did not affect spontaneous locomotor activity in saline-treated mice (Figure 5B).

Effects of Leu-Ile Treatment After the Development of Place Preference and Sensitization Induced by METH in Wild-Type Mice

The therapeutic effects of Leu-Ile on METH-induced place preference were examined. The experimental schedule is described in Figure 1B. Mice were administered Leu-Ile (1.5 and 15 μmol/kg, IP) after the development of METH-induced place preference for 5 days without METH treatment. In this experiment, the second post-conditioning was carried out 5 days after the first post-conditioning. Although METH (1 mg/kg)-induced place preference was maintained for 5 days after the first post-conditioning in wild-type mice, it was attenuated by Leu-Ile treatment (1.5 μmol/kg, IP) for 5 days between the first and second post-conditionings [$F(5,58) = 14.407$, $p < .05$, one-way ANOVA] (Figure 5C).

Next, the therapeutic effects of Leu-Ile on METH-induced sensitization were examined. The experimental schedule is described in Figure 1D. The repeated administration of METH (1 mg/kg, SC) for 9 days resulted in sensitization of METH. Sensitization was observed on day 18 of the administration of METH (1 mg/kg, SC) 5 days after withdrawal from METH [$F(5,154) = 23.107$, $p < .05$, one-way ANOVA]. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) for 5 days during the withdrawal period. Leu-Ile (1.5 and 15 μmol/kg, IP) inhibited METH (1 mg/kg, SC)-induced sensitization on day 18 [$F(3,36) = 21.840$, $p < .05$, one-way ANOVA] (Figure 5D).

We confirmed that Leu-Ile at the low dose, 1.5 μmol/kg, which could inhibit METH-induced rewarding effects, increased GDNF and TNF-α both in combination with METH and after withdrawal from repeated treatment with METH in CPP paradigm. In contrast, Leu-Ile at the higher dose, 15 μmol/kg, which could not inhibit METH-induced rewarding effects, failed to increase them [data not shown; $F(5, 30) = 12.387$ and 19.764 for GDNF and TNF-α levels, respectively, after co-treatment of Leu-Ile and METH in CPP paradigm; $F(3,20) = 12.260$ and 16.670 for GDNF and TNF-α levels, respectively, after Leu-Ile treatment during withdrawal from METH in CPP paradigm]. The results of GDNF and TNF-α contents in the NAc after locomotor test are described in Figures 2D, 2E, 3D, and 3E.

Effects of Leu-Ile on the Rewarding Effects of METH in GDNF-(±) and TNF-α-(−/−) Mice

To confirm the involvement of GDNF and TNF-α in the rewarding effects of METH, the effect of Leu-Ile on METH-induced place preference was examined in GDNF-(±) and TNF-α-(−/−) mice. The experimental schedule is described in Figure 1A. As shown in Figure 6, although at a low dose of METH (.3 mg/kg), GDNF-(+/+) and wild-type mice did not develop place preference, GDNF-(±) and TNF-α-(−/−) mice did [GDNF-(±): $F(7,64) = 6.493$; TNF-α-(−/−): $F(7,56) = 9.514$, $p < .05$, one-way ANOVA]. When Leu-Ile (1.5 and 15 μmol/kg, IP) was administered 1 hour before METH, it failed to exhibit a significant effect on the action of METH in GDNF-(±) and TNF-α-(−/−) mice (Figure 6). These results suggest that GDNF and TNF-α act to negate the rewarding effects of METH and are involved in the effects of Leu-Ile on these rewarding effects.

Effects of Leu-Ile on METH-Induced DA Responses

To explore the mechanisms of the inhibitory effects of Leu-Ile on METH-induced rewarding effects and sensitization, the effects of Leu-Ile on the increase in extracellular DA levels induced by repeated or single METH treatment were examined in the NAc of mice, by using an in vivo microdialysis technique. Repeated and single METH (1 mg/kg, SC) treatment caused a marked increase in extracellular DA levels in the NAc on day 9 and day 1, respectively (Figures 7A and 7B). Peaks of extracellular DA levels were 2.5- and 2.0-fold the baseline, respectively. Treatment with Leu-Ile (1.5 μmol/kg, IP) for 9 days significantly inhibited the repeated METH-induced increase in extracellular DA levels [$F(1,7) = 5.227$, $p < .05$, repeated ANOVA] (Figure 7A). In contrast, pretreatment with Leu-Ile (1.5 μmol/kg, IP) 1 hour before the single METH treatment failed to inhibit the increase in extracellular DA levels (Figure 7B).

We examined the therapeutic effect of Leu-Ile on the METH-induced increase in extracellular DA levels in the NAc of mice after the repeated treatment with METH. As shown in Figure 7C, an acute challenge with METH (1 mg/kg, SC) 5 days after withdrawal caused a marked increase in extracellular DA levels in the NAc of mice treated with vehicle for 5 days during the withdrawal from METH (1 mg/kg, SC). The peak of extracellular DA levels was 2.0-fold the baseline. Leu-Ile (1.5 μmol/kg, IP) treatment for 5 days during the withdrawal from METH significantly attenuated the METH-induced increase in extracellular DA levels [$F(1,14) = 1.689$, $p < .05$, repeated ANOVA] (Figure 7C).

Next, we examined the effect of Leu-Ile on the METH-induced decrease in synaptosomal DA uptake in the midbrain. Repeated METH treatment (1 mg/kg, SC) caused a decrease in [^{3}H] DA uptake by 38% compared with the vehicle/saline-treated mice. Leu-Ile (1.5 μmol/kg, IP) inhibited the METH-induced decrease in synaptosomal [^{3}H] DA uptake [$F(3,28) = 12.477$, $p < .05$, one-way ANOVA] (Figure 7D).

Finally, we examined the therapeutic effect of Leu-Ile on the METH-induced decrease in synaptosomal DA uptake in the midbrain. As shown in Figure 7E, an acute challenge with METH (1 mg/kg, SC) after treatment with vehicle for 5 days during withdrawal from METH caused a decrease in [^{3}H] DA uptake by 51% in the midbrain compared with the saline/vehicle/METH-treated mice. Leu-Ile (1.5 μmol/kg, IP) treatment for 5 days



Figure 2. Effect of Leu-Ile on methamphetamine (METH)-induced increase in glial cell line-derived neurotrophic factor (GDNF) levels. **(A)** The dose-response stimulatory effects of Leu-Ile on GDNF levels in cultured neurons. Corti-hippocampal neurons of 18-day-old rat embryos were cultured in serum-free defined medium containing Leu-Ile (.037, .37, 3.7, and 37 μg/mL). The GDNF levels were determined 24 hours after the addition of Leu-Ile by enzyme immunoassay. Values are means ± SEM (n = 5–10). *p < .05 versus control subjects. **(B)** The time-course stimulatory effects of Leu-Ile on the expression of GDNF messenger RNA in cultured neurons. Corti-hippocampal neurons of 18-day-old rat embryos were cultured in serum-free defined medium containing Leu-Ile (.37 μg/mL). Total RNA was prepared 6, 12, and 24 hours after the addition of Leu-Ile. Values are means ± SEM (n = 8). *p < .05 versus control subjects. **(C)** Immunostaining of GDNF in the nucleus accumbens (NAc) after the administration of Leu-Ile and/or METH **(a)**. Double-labeling fluorescence photomicrographs for GDNF and microtuble-associated protein-2 (MAP2) or glial fibrillary acidic protein (GFAP) **(b)**. The GDNF-immunoreactive cells (red) were colocalized with MAP2-positive and GFAP-positive cells (green) in the NAc. Double immunostaining for GDNF and MAP2 or GFAP in the NAc reveals GDNF expression in neuronal and astro glial cells. Scale bars, 20 μm. **(D)** Change of GDNF levels in the NAc after the administration of Leu-Ile and/or METH. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) 1 hour before METH (1 mg/kg, SC) once/day for 9 days and decapitated 24 hours after the last METH injection. Values are means ± SEM (n = 6–8). *p < .05 versus vehicle/saline-treated mice. #p < .05 versus vehicle/METH-treated mice. **(E)** Change of GDNF levels in the NAc after Leu-Ile treatment during the withdrawal from METH. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) for 5 days after the development of METH (1 mg/kg, SC)-induced sensitization. The next day, the mice were administered only METH (1 mg/kg, SC) and decapitated 24 hours after the administration. Values are means ± SEM (n = 6). *p < .05 versus saline/vehicle/METH-treated mice. #p < .05 versus METH/vehicle/METH-treated mice.



Figure 3. Effect of Leu-Ile on METH-induced increase in tumor necrosis factor-α (TNF-α) levels. **(A)** The dose-response stimulatory effects of Leu-Ile on the expression of TNF-α messenger RNA (mRNA) in cultured neurons. Corti-hippocampal neurons of 18-day-old rat embryos were cultured in serum-free defined medium containing Leu-Ile (.037, .37, 3.7, and 37 μg/mL). Total RNA was prepared 24 hours after the addition of Leu-Ile. Values are means ± SEM ($n = 7$). *$p <$ .05 versus control subjects. **(B)** The time-course stimulatory effects of Leu-Ile on the expression of TNF-α mRNA in cultured neurons. Corti-hippocampal neurons of 18-day-old rat embryos were cultured in serum-free defined medium containing Leu-Ile (.37 μg/mL). Total RNA was prepared 6, 12, and 24 hours after the addition of Leu-Ile. Values are means ± SEM ($n = 8$). *$p < .05$ versus control subjects. **(C)** Immunostaining of TNF-α in the NAc after the administration of Leu-Ile and/or METH **(a)**. Double-labeling fluorescence photomicrographs for TNF-α and MAP2 or GFAP **(b)**. The TNF-α-immunoreactive cells (red) were colocalized with MAP2-positive cells (green) in the NAc. Double immunostaining for TNF-α and MAP2 in the NAc reveals TNF-α expression in neuronal cells. Scale bars, 100 **(a)** and 20 **(b)** μm. **(D)** Change of TNF-α expression in the NAc after the administration of Leu-Ile and/or METH. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) 1 hour before METH (1 mg/kg, SC) for 9 days and decapitated 24 hours after the last METH injection. The area of TNF-α positive cells in 3.8×10^4 μm^2 was estimated with the software WinRoof. Values are means ± SEM ($n = 6–8$). *$p < .05$ versus vehicle/saline-treated mice. #$p < .05$ versus vehicle/METH-treated mice. **(E)** Change of TNF-α expression in the NAc after Leu-Ile treatment during the withdrawal from METH. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) for 5 days after the development of METH (1 mg/kg, SC)-induced sensitization. The next day, the mice were administered only METH (1 mg/kg, SC) and decapitated 24 hours after the administration. Values are means ± SEM ($n = 6–8$). *$p < .05$ versus saline/vehicle/METH-treated mice. #$p < .05$ versus METH/vehicle/METH-treated mice. **(F)** Tumor necrosis factor-α concentration in peripheral blood after the treatment with Leu-Ile. Mice were treated with Leu-Ile (1.5 μmol/kg, IP), and venous blood was collected 0, 1, 2, 4, and 8 hours after the injection **(a)**. Values are means ± SEM ($n = 4$) (upper panel). Mice were treated with TNF-α (4 μg/body, IP), and venous blood was collected 1, 2, and 4 hours after the injection **(b)**. Values are means ± SEM ($n = 3–4$) (lower panel). The concentration of TNF-α was measured with a mouse TNF-α (upper panel) or human TNF-α enzyme-linked immunosorbent assay (ELISA) kit (lower panel). *$p < .05$ versus vehicle-treated mice. Other abbreviations as in Figure 2.



Figure 4. Regulatory effect of TNF-α on GDNF expression in cultured neurons. **(A)** The dose-response stimulatory effects of TNF-α on the expression of GDNF messenger RNA (mRNA) in cultured neurons. Corti-hippocampal neurons of 18-day-old rat embryos were cultured in serum-free defined medium containing TNF-α (20 and 100 ng/mL). Total RNA was prepared 24 hours after the addition of TNF-α. Values are means ± SEM (n = 4–5). *$p < .05$ versus control subjects. **(B)** The time-course stimulatory effects of TNF-α on the expression of GDNF mRNA in cultured neurons. Corti-hippocampal neurons of 18-day-old rat embryos were cultured in serum-free defined medium containing TNF-α (100 ng/mL). Total RNA was prepared 6, 12, and 24 hours after the addition of TNF-α. Values are means ± SEM (n = 8–12). *$p < .05$ versus control subjects. **(C)** The dose-response stimulatory effects of TNF-α on GDNF levels in the cultured neurons. Corti-hippocampal neurons of 18-day-old rat embryos were cultured in serum-free defined medium containing TNF-α (2, 20, 100, and 200 ng/mL). The GDNF levels were determined 24 hours after the addition of TNF-α by enzyme immunoassay. Values are means ± SEM (n = 5–10). *$p < .05$ versus control subjects. Other abbreviations as in Figure 2.

during the withdrawal from METH inhibited the METH-induced decrease in synaptosomal [^{3}H] DA uptake [$F(2,21) = 7.544$, $p < .05$, one-way ANOVA] (Figure 7E).

Discussion

There are currently few efficacious medications for drug dependence. Recently, it has been reported that an opioid κ receptor agonist, TRK-820, inhibits not only the rewarding effects of morphine and cocaine but also a mecamylamine-precipitated nicotine-withdrawal aversive effect (Mori *et al.* 2002; Tsuji *et al.* 2001). A DA D3 receptor partial agonist, BP897affects cocaine-associated stimulus-induced drug-seeking behavior in rats (Cervo *et al.* 2003). These medications should be effective even when they are administered after the development of drugs of abuse. In this study, the METH-induced place preference and sensitization that formed before Leu-Ile treatment were attenuated by Leu-Ile (Figures 5C and 5D), by regulating extracellular DA levels (Figures 7C and 7E). These results suggest that Leu-Ile could be a novel therapeutic agent for dependence on METH.

Leu-Ile increased GDNF levels in the cultured neurons (Figures 2A and 2B). In vivo, Leu-Ile treatment both in combination with METH and after withdrawal from repeated treatment with METH also increased GDNF levels (Figures 2D and 2E). We have previously demonstrated that Leu-Ile targets the Hsc70/Hsp90 cochaperone and, thus, triggers Akt/CREB signaling, resulting in an upregulation of GDNF expression (Cen *et al.* 2006). In addition, Leu-Ile treatment, both in combination with METH and after withdrawal from repeated treatment with METH, inhibited place preference and sensitization to METH (Figure 5). Glial cell line-derived neurotrophic factor blocks the ability of cocaine and morphine to increase levels of tyrosine hydroxylase in the VTA and blunts the biochemical and behavioral responses to chronic cocaine or morphine exposure (Messer *et al.* 2000). Glial cell line-derived neurotrophic factor decreases tyrosine hydroxylase levels in normal animals, suggesting an active down-regulation of the synthesis of this enzyme (Lu and Hagg 1997). These results suggest that Leu-Ile plays an inhibitory role in the rewarding effects and sensitization induced by METH via the induction of GDNF expression.

As described at the beginning of this article, TNF-α induces GDNF expression and blocks METH-induced dependence. Therefore, we investigated whether Leu-Ile induces the expression of TNF-α. Leu-Ile increased TNF-α mRNA levels in the cultured neurons (Figures 3A and 3B). In vivo, Leu-Ile treatment, both in combination with METH and after withdrawal from repeated treatment with METH, also increased TNF-α levels (Figures 3D and 3E) in the brain but not in the peripheral blood stream (Figure 3F). Leu-Ile can penetrate the BBB and initiate the synthesis of GDNF in the brain (Nitta *et al.* 2004). Therefore, we suggest that Leu-Ile penetrates the BBB and induces TNF-α expression only in the brain. The expression of TNF-α is induced through the activation of transcription factors such as activator protein-1 and nuclear factor-κB (NF-κB) (Guha *et al.* 2000; Rahman and MacNee 2000). Changes in transcription factors might result in long-term changes in gene expression, thereby contributing to neuronal adaptations that underlie behavioral sensitization to chronic psychostimulant treatment (Nestler 2001). Furthermore, TNF-α influences synaptic strength and transmission (Albensi and Mattson 2000; Beattie *et al.* 2002). Collectively, these observations lead to the hypothesis that Leu-Ile might have inhibitory effects on long-lasting behavioral changes induced by repeated METH treatment via the induction of TNF-α expression.

Tumor necrosis factor-α was expressed in the neurons of the NAc after the co-administration of Leu-Ile with METH (Figure 3C), whereas GDNF was expressed in the neuronal and astro glial cells (Figure 2C). Therefore, TNF-α expression induced by Leu-Ile might regulate GDNF expression in neuronal cells, although little is known about the regulation of GDNF synthesis in the brain. It has been reported that GDNF expression in astrocytes can be induced by inflammatory stimuli such as TNF-α and lipopolysaccharide (Appel *et al.* 1997). These previous reports have suggested that the induction of GDNF expression might be regulated through production of TNF-α. In the present study, TNF-α increased GDNF expression in the cultured neu-



Figure 5. Effects of Leu-Ile on methamphetamine (METH)-induced place preference and hyperlocomotion/sensitization in wild-type mice. **(A)** Effect of Leu-Ile on METH-induced place preference in wild-type mice. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) 1 hour before receiving METH (1 mg/kg, SC) or saline during the conditioning. Values are means ± SEM (n = 9–10). $^{*}p < .05$ versus vehicle/saline-treated mice. $^{\#}p < .05$ versus vehicle/METH-treated mice. **(B)** Effect of Leu-Ile on METH-induced hyperlocomotion and sensitization in wild-type mice. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) 1 hour before the METH (1 mg/kg, SC) injection. Values are means ± SEM (n = 10). Locomotor activity was measured for 2 hours after the METH treatment. Analysis of variance with repeated measures revealed significant differences in the locomotor activity [$F(5,54) = 59.1278$, $p < .05$]. $^{*}p < .05$ versus vehicle/saline-treated mice. $^{\#}p < .05$ versus vehicle/METH-treated mice. $^{\$}p < .05$ versus vehicle/METH-treated mice on day 4. **(C)** Effect of Leu-Ile treatment after the development of place preference induced by METH in wild-type mice. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) for 5 days after withdrawal from METH. Values are means ± SEM (n = 7–10). $^{*}p < .05$ versus saline/vehicle-treated mice. $^{\#}p < .05$ versus METH/vehicle-treated mice. **(D)** Effect of Leu-Ile treatment after the development of METH-induced sensitization in wild-type mice. Mice were treated with Leu-Ile (1.5 and 15 μmol/kg, IP) for 5 days after the development of METH (1 mg/kg, SC)-induced sensitization. Values are means ± SEM (n = 10). Locomotor activity was measured for 2 hours after the METH treatment on day 18. $^{*}p < .05$ versus saline/vehicle/METH-treated mice. $^{\#}p < .05$ versus METH/vehicle/METH-treated mice.

rons (Figure 4). Furthermore, Leu-Ile induced GDNF and TNF-α expression (Figures 2 and 3). Therefore, Leu-Ile might induce GDNF as a result of TNF-α expression to inhibit METH-induced rewarding effects and sensitization, although another signal pathway should be considered—that Leu-Ile upregulates GDNF expression by activating Hsp90/Akt/CREB signaling (Cen *et al.* 2006).

Leu-Ile increased GDNF and TNF-α expression in the cultured neurons (Figures 2A and 3A) and inhibited METH-induced place preference (Figures 5A and 5C) in bell-shaped response curves. It has been reported that TNF-α, reactive oxygen species (H_2O_2), and β-amyloid activate NF-κB in bell-shaped dose-response curves (Kaltschmidt *et al.* 1999). Rasagiline, an anti-Parkinson drug, activates NF-κB and increases GDNF in bell-shaped dose-response curves (Maruyama *et al.* 2004). We confirmed that Leu-Ile at the lower dose, 1.5 μmol/kg, which could inhibit the rewarding effects of METH, increased GDNF and TNF-α expression both in combination with METH and after withdrawal from repeated METH treatment in the CPP paradigm. Conversely, Leu-Ile at the higher dose, 15 μmol/kg, which could not inhibit the rewarding effects of METH, failed to increase GDNF and TNF-α levels (data not shown). These results suggest involvement of induction of GDNF and TNF-α expression in inhibitory effect of Leu-Ile on the rewarding effects and sensitization of METH.

Leu-Ile attenuated the METH-induced place preference (Figure 5A). Glial cell line-derived neurotrophic factor and TNF-α could be involved in the inhibitory effects of Leu-Ile on the rewarding effects of METH, because no effects of Leu-Ile were observed in the GDNF-(±) and TNF-α-(−/−) mice (Figure 6). These findings support that GDNF and TNF-α play important roles in METH-induced behavioral changes and suggest that Leu-Ile attenuates rewarding effects via the induction of GDNF and TNF-α expression.

The mesolimbic dopaminergic pathway projecting from the VTA to NAc is considered to play a major role in mediating the rewarding effects of electrical stimulation of the brain and drugs of abuse (Everitt and Wolf 2002; Koob 1992; Koob *et al.* 1998). This pathway is important not only for the rewarding effects but also for the locomotor-stimulating effects of METH (Mizoguchi *et al.* 2004; Nagai *et al.* 2005b; Nakajima *et al.* 2004). Leu-Ile inhibited METH-induced hyperlocomotion and sensitization (Figures 5B and 5D), at least in part, through the NAc, because it showed inhibitory effects on the increase in extracellular DA levels induced by repeated METH treatment (Figures 7A and 7C) and the decrease in synaptosomal DA uptake (Figures 7D and 7E) in the NAc. Although Leu-Ile failed to inhibit the hyperlocomotion induced by single METH treatment, it inhibited repeated METH-induced sensitization (Figure 5B). These results suggest that Leu-Ile has inhibitory effects on neuronal plasticity induced by repeated METH treatment but not on single METH-induced hyperlocomotion or the increase in extracellular DA levels (Figure 7B). Because acute treatment of Leu-Ile failed to inhibit single METH-induced hyperlocomotion and the increase in extracellular DA levels, the induction of GDNF and TNF-α expression requires repeated treatment of Leu-Ile.

We have previously reported that TNF-α attenuates the METH-induced increase in extracellular DA levels and potentiates DA uptake into synaptic vesicles and negates METH-induced inhibition of DA uptake in the striatum (Nakajima *et al.* 2004). We

have also demonstrated that the tissue plasminogen activator-plasmin system accelerates the release of DA, which is involved in the rewarding effects of METH and morphine (Nagai *et al.* 2004, 2005a, 2005b). In the present study, we demonstrated that Leu-Ile attenuated the increase in extracellular DA levels in the NAc induced by repeated METH treatment (Figures 7A and 7C) and negated METH-induced inhibition of DA uptake in the midbrain (Figures 7D and 7E). The inhibition of the METH-induced increase in extracellular DA levels and decrease of DA uptake by repeated Leu-Ile treatment might be one plausible mechanism by which Leu-Ile inhibits METH-induced chronic behavioral changes via the induction of TNF-α expression. One might consider that TNF-α could attenuate the rewarding effects and sensitization of other drugs of abuse if it activates DA uptake and thereby attenuates the METH-induced increase in extracellular DA levels. Our results have shown that TNF-α or Leu-Ile inhibits morphine-induced place preference and sensitization by regulating extracellular DA levels (Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Noda Y, and Nabeshima T, unpublished observations). These observations support our hypothesis about effect of Leu-Ile on drug abuse.



Figure 6. Effect of Leu-Ile on METH-induced place preference in GDNF-(±) and TNF-α-(−/−) mice. **(A)** Effect of Leu-Ile treatment on METH-induced place preference in GDNF-(±) mice. Mice were treated with METH (.3 mg/kg, SC) or saline during the conditioning. Values are means ± SEM (n = 7–12). *p < .05 versus vehicle/METH-treated GDNF-(+/+) mice. **(B)** Effect of Leu-Ile treatment on METH-induced place preference in TNF-α-(−/−) mice. Mice were treated with METH (.3 mg/kg, SC) or saline during the conditioning. Values are means ± SEM (n = 8). *p < .05 versus vehicle/METH-treated wild-type mice. Abbreviations as in Figure 2.



Figure 7. Effect of Leu-Ile on methamphetamine (METH)-induced dopamine (DA) responses. **(A)** In vivo effect of Leu-Ile on the increase in extracellular DA levels induced by repeated METH treatment. Mice were treated with Leu-Ile (1.5 μmol/kg, IP) 1 hour before METH (1 mg/kg, SC) once/day for 9 days. Basal extracellular DA levels were .50 ± .10 and .81 ± .35 nmol/L for the vehicle/METH- and Leu-Ile/METH-treated mice, respectively. Values are means ± SEM (n = 4–5). *p < .05 versus vehicle/METH-treated mice. **(B)** In vivo effect of Leu-Ile on the increase in extracellular DA levels induced by single METH treatment. Mice were treated with Leu-Ile (1.5 μmol/kg, IP) once, 1 hour before receiving METH (1 mg/kg, SC). Basal extracellular DA levels were .81 ± .09 and .80 ± .12 nmol/L for the vehicle/METH- and Leu-Ile/METH-treated mice, respectively. Values are means ± SEM (n = 5). **(C)** In vivo effect of Leu-Ile treatment during the withdrawal from METH on the METH-induced increase in extracellular DA levels. Mice were treated with Leu-Ile (1.5 μmol/kg, IP) for 5 days during the withdrawal from METH (1 mg/kg, SC). Basal extracellular DA levels were .27 ± .02 and .24 ± .01 nmol/L for the METH/vehicle- and METH/Leu-Ile-treated mice, respectively. Values are means ± SEM (n = 8). **(D)** Effect of Leu-Ile on the decrease in synaptosomal DA uptake induced by repeated METH treatment. Mice were treated with Leu-Ile (1.5 μmol/kg, IP) 1 hour before METH (1 mg/kg, SC) once/day for 9 days and decapitated 1 hour after the last METH treatment. The synaptosomal [^{3}H] DA uptake was .47 ± .10, .61 ± .10, .13 ± .03, and .39 ± .05 pmol/4-min/mg protein for vehicle/saline-treated, Leu-Ile/saline-treated, vehicle/METH-treated, and Leu-Ile/METH-treated mice, respectively. The final concentration of [^{3}H] DA was 5 nmol/L. Values are means ± SEM (n = 8). *p < .05 versus vehicle/saline-treated mice. $^{\#}p$ < .05 versus Leu-Ile/saline-treated mice. $^{\$}p$ < .05 versus vehicle/METH-treated mice. **(E)** The therapeutic effect of Leu-Ile on the decrease in synaptosomal DA uptake induced by repeated METH treatment. Mice were treated with Leu-Ile (1.5 μmol/kg, IP) for 5 days after the development of METH (1 mg/kg, SC)-induced sensitization. The next day, the mice were administered only METH (1 mg/kg, SC) and decapitated 1 hour after the administration. The synaptosomal [^{3}H] DA uptake was .50 ± .06, .25 ± .03, and .43 ± .05 pmol/4-min/mg protein for saline/vehicle/METH-treated, METH/vehicle/METH-treated, and METH/Leu-Ile/METH-treated mice, respectively. The final concentration of [^{3}H] DA was 5 nmol/L. Values are means ± SEM (n = 8). *p < .05 versus saline/vehicle/METH-treated mice. $^{\#}p$ < .05 versus METH/vehicle/METH-treated mice.

It has been reported that Leu-Ile induces the expression of brain-derived neurotropic factor (BDNF) (Nitta *et al.* 2004) in addition to that of GDNF and TNF-α. Infusion of BDNF into the NAc enhances the stimulation of locomotor activating by cocaine in rats, whereas the development of sensitization and CPP is delayed in heterozygous BDNF knockout mice compared with wild-type littermates (Hall *et al.* 2003; Horger *et al.* 1999). These results suggest a possible role for BDNF in long-term adaptations of the brain to cocaine (Yamada and Nabeshima 2004). In the present study, we targeted anti-addictive factors like GDNF and TNF-α but not pro-addictive factors like BDNF to find a new therapeutic agent for drug dependence. As shown in bell-shaped dose-response curves described previously, the narrow effective dose range of Leu-Ile might be due to the balance of level between anti- and pro-addictive factors induced by Leu-Ile.

Our findings suggest that Leu-Ile has inhibitory effects on METH-induced rewarding effects and sensitization by negating the METH-induced inhibition of DA uptake as well as attenuating the METH-induced increase in extracellular DA levels in the NAc via the induction of GDNF and TNF-α expression. Leu-Ile could be a novel therapeutic agent for METH-induced dependence.

This study was supported in part by a Grant-in-aid for Scientific Research and Special Coordination Funds for Promoting Science and Technology, Target-Oriented Brain Science Research Program; by a Grant-in-aid for Scientific Research (B) and Young Scientists (A); by the 21st Century Center of Excellence Program "Integrated Molecular Medicine for Neuronal and Neoplastic Disorders" from the Ministry of Education, Culture, Sports, Science and Technology of Japan; by a Grant-in-aid for Health Science Research on Regulatory Science of Pharmaceuticals and Medical Devices, and Comprehensive Research on Aging and Health from the Ministry of Health, Labor and Welfare of Japan; by a Smoking Research Foundation Grant for Biomedical Research; by the Mochida Memorial Foundation for Medical and Pharmaceutical Research; by a grant from the Brain Research Center from 21st Century Frontier Research Program funded by the Ministry of Science and Technology, Republic of Korea; and by Japan Canada Joint Health Research Program.

The authors are grateful to Amgen and Dainippon Pharmaceutical Co., Ltd. for the supply of recombinant human GDNF and TNF-α, respectively, and to Dr. Kiyoyuki Kitaichi, Nagasaki International University, for his help collecting blood.

Albensi BC, Mattson MP (2000): Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. *Synapse* 35:151–159.

Appel E, Kolman O, Kazimirsky G, Blumberg PM, Brodie C (1997): Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli. *Neuroreport* 8:3309–3312.

Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, *et al.* (2002): Control of synaptic strength by glial TNF alpha. *Science* 295:2282–2285.

Bluthe RM, Pawlowski M, Suarez S, Parnet P, Pittman Q, Kelley KW, *et al.* (1994): Synergy between tumor necrosis factor alpha and interleukin-1 in the induction of sickness behavior in mice. *Psychoneuroendocrinology* 19:197–207.

Boulanger L, Poo M (1999): Gating of BDNF-induced synaptic potentiation by cAMP. *Science* 284:1982–1984.

Cen X, Nitta A, Ohya S, Zhao Y, Ozawa N, Mouri A, *et al.* (2006): An analogue of dipeptide-like structure of FK506 increases GDNF expression through CREB activated by Hsp90/Akt signaling pathway. *J Neurosci* 26:3335–3344.

Cervo L, Carnovali F, Stark JA, Mennini T (2003): Cocaine-seeking behavior in response to drug-associated stimuli in rats: Involvement of D3 and D2 dopamine receptors. *Neuropsychopharmacology* 28:1150–1159.

Connor B, Dragunow M (1998): The role of neuronal growth factors in neurodegenerative disorders of the human brain. *Brain Res Brain Res Rev* 27:1–39.

Everitt BJ, Wolf ME (2002): Psychomotor stimulant addiction: A neural systems perspective. *J Neurosci* 22:3312–3320.

Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson G (1997): Rapid and reversible effects of methamphetamine on dopamine transporters. *J Pharmacol Exp Ther* 282:834–838.

Franklin KBJ, Paxinos G (1997): *The Mouse Brain in Stereotaxic Coordinates.* San Diego, California: Academic Press.

Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996): Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature* 379:606–612.

Guha M, Bai W, Nadler JL, Natarajan R (2000): Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. *J Biol Chem* 275:17728–17739.

Hall FS, Drgonova J, Goeb M, Uhl GR (2003): Reduced behavioral effects of cocaine in heterozygous brain-derived neurotropic factor (BDNF) knockout mice. *Neuropsychopharmacology* 28:1485–1490.

Heikkila RE, Orlansky H, Cohen G (1975): Studies on the distinction between uptake inhibition and release of ^{3}H-dopamine in rat brain tissue slices. *Biochem Pharmacol* 24:847–852.

Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR (1999): Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotropic factor. *J Neurosci* 19:4110–4122.

Kaltschmidt B, Uherek M, Wellmann H, Volk B, Kaltschmidt C (1999): Inhibition of NF-κB potentiates amyloid β-mediated neuronal apoptosis. *Proc Natl Acad Sci U S A* 96:9409–9414.

Koob GF (1992): Drugs of abuse: Anatomy, pharmacology and function of reward pathways. *Trends Pharmacol Sci* 13:177–184.

Koob GF, Sanna PP, Bloom FE (1998): Neuroscience of addiction. *Neuron* 21:467–476.

Kuwahara M, Sugimoto M, Tsuji S, Miyata S, Yoshida A (1999): Cytosolic calcium changes in a process of platelet adhesion and cohesion on a von Willebrand factor-coated surface under flow conditions. *Blood* 94:1149–1155.

Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993): GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* 260:1130–1132.

Lu X, Hagg H (1997): Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats. *J Comp Neurol* 388:484–494.

Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Yodim M, *et al.* (2004): N-Propargyl-1 (*R*)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. *Neurochem Int* 44:393–400.

Messer CJ, Eisch AJ, Carlezon WA Jr., Whisler K, Shen L, Wolf DH, *et al.* (2000): Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. *Neuron* 26:247–257.

Mizoguchi H, Yamada K, Mizuno M, Mizuno T, Nitta A, Noda Y, *et al.* (2004): Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors. *Mol Pharmacol* 65:1293–1301.

Mori T, Nomura M, Nagase H, Narita M, Suzuki T (2002): Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. *Psychopharmacology* 161:17–22.

Nagai T, Kamei H, Ito M, Hashimoto K, Takuma K, Nabeshima T, *et al.* (2005a): Modification by the tissue plasminogen activator-plasmin system of morphine-induced dopamine release and hyperlocomotion, but not anti-nociceptive effect in mice. *J Neurochem* 93:1272–1279.

Nagai T, Noda Y, Ishikawa K, Miyamoto Y, Yoshimura M, Ito M, *et al.* (2005b): The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. *J Neurochem* 92:660–667.

Nagai T, Yamada K, Yoshimura M, Ishikawa K, Miyamoto Y, Hashimoto K, *et al.* (2004): The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. *Proc Natl Acad Sci U S A* 101:3650–3655.

Nakajima A, Yamada K, Nagai T, Uchiyama T, Miyamoto Y, Mamiya T, *et al.* (2004): Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. *J Neurosci* 24:2212–2225.

Nestler EJ (2001): Molecular basis of long-term plasticity underlying addiction. *Nat Rev Neurosci* 2:119–128.

Neumann H, Schweigreiter R, Yamashita T, Rosenkranz K, Wekerle H, Barde Y (2002): Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a Rho-dependent mechanism. *J Neurosci* 22:854–862.

Nitta A, Ito M, Fukumitsu H, Ohmiya M, Ito H, Sometani A, *et al.* (1999a): 4-methylcatechol increases brain-derived neurotrophic factor content and mRNA expression in cultured brain cells and in rat brain in vivo. *J Pharmacol Exp Ther* 291:1276–1283.

Nitta A, Nishioka H, Fukumitsu H, Furukawa Y, Sugiura H, Shen L, *et al.* (2004): Hydrophobic dipeptide Leu-Ile protects against neuronal death by inducing brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis. *J Neurosci Res* 78:250–258.

Nitta A, Ohmiya M, Sometani A, Itoh M, Nomoto H, Furukawa Y, *et al.* (1999b): Brain-derived neurotrophic factor prevents neuronal cell death induced by corticosterone. *J Neurosci Res* 57:227–235.

Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, *et al.* Tumor necrosis factor-α and its inducer inhibit morphine-induced rewarding effects and sensitization. Submitted.

Noda Y, Miyamoto Y, Mamiya T, Kamei H, Furukawa H, Nabeshima T (1998): Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly. *J Pharmacol Exp Ther* 286:44–51.

Pichel JG, Shen L, Sheng HZ, Granholm AC, Drago J, Grinberg A, *et al.* (1996): Defects in enteric innervation and kidney development in mice lacking GDNF. *Nature* 382:73–76.

Rahman I, MacNee W (2000): Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. *Free Radic Biol Med* 28:1405–1420.

Robbins TW, Everitt BJ (1999): Drug addiction: Bad habits add up. *Nature* 398:567–570.

Robinson TE, Kolb B (1997): Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. *J Neurosci* 17:8491–8497.

Robinson TE, Kolb B (1999): Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. *Eur J Neurosci* 11:1598–1604.

Seiden LS, Sabol KE, Ricaurte GA (1993): Amphetamine: Effects on catecholamine systems and behavior. *Annu Rev Pharmacol Toxicol* 33: 639–677.

Taniguchi T, Tanaka M, Ikeda A, Momotani E, Sekikawa K (1997): Failure of germinal center formation and impairment of response to endotoxin in tumor necrosis factor α deficient mice. *Lab Invest* 77:647–658.

Tsuji M, Takeda H, Matsumiya T, Nagase H, Narita M, Suzuki T (2001): The novel κ-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. *Life Sci* 68:1717–1725.

Tsuji S, Sugimoto M, Miyata S, Kuwahara M, Kinoshita S, Yoshioka A (1999): Real-time analysis of mural thrombus formation in various platelet aggregation disorders: Distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. *Blood* 94:968–975.

Wada R, Tifft CJ, Proia RL (2000): Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. *Proc Natl Acad Sci U S A* 97:10954–10959.

Yamada K, Iida R, Miyamoto Y, Saito K, Sekikawa K, Sedishima M, *et al.* (2000): Neurobehavioral alternations in mice with a targeted deletion of the tumor necrosis factor-alpha gene: Implication for emotional behavior. *J Neuroimmunol* 111:131–138.

Yamada K, Nabeshima T (2004): Pro- and anti-addictive neurotrophic factors and cytokines in psychostimulant addiction: Mini review. *Ann N Y Acad Sci* 1025:198–204.

Tumor Necrosis Factor-α and Its Inducer Inhibit Morphine-Induced Rewarding Effects and Sensitization

Minae Niwa, Atsumi Nitta, Yuichiro Yamada, Akira Nakajima, Kuniaki Saito, Mitsuru Seishima, Yukihiro Noda, and Toshitaka Nabeshima

Background: Tumor necrosis factor-α (TNF-α) is emerging as an important modulator of the function of the central nervous system (CNS). We have demonstrated that TNF-α or Leu-Ile, a TNF-α inducer, inhibits methamphetamine-induced rewarding effects and sensitization. In this study, we investigated the effects of TNF-α or Leu-Ile on morphine (MOR)-induced rewarding effects and sensitization.

Methods: Levels of TNF-α messenger RNA (mRNA) and protein were determined by real-time reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry. Effects of TNF-α or Leu-Ile on MOR-induced rewarding effects and sensitization were investigated by conditioned place preference and locomotor activity tests. Extracellular dopamine levels were examined using in vivo microdialysis. Effects of TNF-α or Leu-Ile on MOR-induced antinociceptive effect and withdrawal symptoms were examined by hot plate test and naloxone-preciptated withdrawal.

Results: Morphine induced TNF-α mRNA expression via dopamine and opioid receptors. Posttreatment with TNF-α or Leu-Ile attenuated the MOR-induced place preference and sensitization even after their development, as well as pretreatment with TNF-α or Leu-Ile blocked them. An inhibitory effect of Leu-Ile on MOR-induced place preference was not observed in TNF-α knockout mice. Tumor necrosis factor-α or Leu-Ile inhibited the increase in extracellular dopamine levels in the nucleus accumbens induced by repeated MOR treatment.

Conclusions: These results suggest that TNF-α inhibits MOR-induced rewarding effect and sensitization by regulating extracellular dopamine levels, and Leu-Ile inhibits them via the induction of TNF-α.

Key Words: Dopamine (DA), Leu-Ile, morphine (MOR), rewarding effect, sensitization, tumor necrosis factor-α (TNF-α)

Tumor necrosis factor-α (TNF-α) plays an important role in a variety of infectious, inflammatory, and autoimmune conditions (Vassali 1992). Tumor necrosis factor-α also affects the central nervous system (CNS) directly or indirectly through the stimulation of vagal afferents (Maier and Watkins 1998). Thus, this proinflammatory cytokine is emerging as a modulator of CNS function. Regarding the behavioral effects of TNF-α, transgenic mice expressing high levels of TNF-α in the brain showed several changes in exploratory activity and emotional behavior in association with reduced tyrosine hydroxylase (TH) immunoreactivity in the caudate putamen (CPu) without neuronal cell death (Aloe and Fiore 1997). On the other hand, TNF-α knockout mice show anxiogenic-like behavior accompanied by an increase in serotonin metabolism (Yamada *et al.* 2000).

Recently, we have demonstrated that TNF-α plays a neuroprotective role in methamphetamine (METH)-induced drug dependence and neurotoxicity by inhibiting the METH-induced increase in extracellular dopamine (DA) levels through activation of plasmalemmal dopamine transporter (DAT) as well as vesicular monoamine transporter-2 (Nakajima *et al.* 2004). Furthermore, we have demonstrated that Leu-Ile, which induces glial cell line-derived neurotrophic factor (GDNF) production via TNF-α synthesis, inhibits METH-induced rewarding effect and sensitization by regulating extracellular DA levels in the nucleus accumbens (NAc) (Niwa *et al*, in press).

The psychostimulative effects of METH are associated with an increase in extracellular DA levels in the brain by facilitating the release of DA from presynaptic nerve terminals and inhibiting reuptake (Giros *et al.* 1996; Heikkila *et al.* 1975; Kalivas and Stewart 1991; Seiden *et al.* 1993). It is well known that drugs of abuse, including METH and morphine (MOR), modulate the activity of mesolimbic dopaminergic neurons, projecting from the ventral tegmental area (VTA) of the midbrain to the NAc (Koob 1992, 1998; Wise 1996). Brain DA systems have also been focused on in histochemical, biochemical, and pharmacological research into psychological dependence on opioids, such as MOR (Funada *et al.* 1993; Narita *et al.* 2001). Morphine increases dopaminergic neurotransmission in the NAc via the activation of DA cells in the VTA, an area with a high density of μ-opioid receptors. This activation results mainly from the disinhibition of inhibitory γ-aminobutyric acid (GABA)ergic interneurons in the VTA (Bonci and Williams 1997; Johnson and North 1992). Various studies have provided substantial evidence to support roles for mesolimbic dopaminergic transmission in the rewarding effects of and behavioral sensitization to opioids (Vezina and Stewart 1984). Further, it has been proposed that activity-dependent synaptic plasticity and remodeling of the mesolimbic dopaminergic system play a crucial role in the development of drug dependence (Nestler 2001).

We hypothesized that those genes whose expression was altered by repeated administration of METH and MOR could be candidates for drug-dependence-related genes, because both METH and MOR increase dopaminergic neurotransmis-

From the Department of Neuropsychopharmacology and Hospital Pharmacy (MN, AN, YY, AN, YN, TN), Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Informative Clinical Medicine (KS, MS), Gifu University Graduate School of Medicine, Gifu, Japan; and Division of Clinical Science in Clinical Pharmacy Practice (YN), Management and Research, Faculty of Pharmacy, Meijo University, Nagoya, Japan.

Address reprint requests to Toshitaka Nabeshima, Ph.D., Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8560, Japan; E-mail: tnabeshi@med.nagoya-u.ac.jp.

Received May 23, 2006; revised September 30, 2006; accepted October 4, 2006.

0006-3223/07/$32.00
doi:10.1016/j.biopsych.2006.10.009

sion in the NAc (Nagai *et al.* 2004, 2005a, 2005b; Niwa *et al*, in press).

To build on our findings, in the present study we examined the roles of TNF-α and Leu-Ile in the rewarding effect and the sensitization to the locomotor-stimulating effects of MOR.

Methods and Materials

Reagents

Tumor necrosis factor-α was donated by Dainippon Pharmaceutical Co., Ltd. (Osaka, Japan). Leu-Ile was purchased from Kokusan Chemical Co., Ltd. (Tokyo, Japan). All other materials used were of reagent grade.

Animals

Animals were housed in plastic cages and kept in a temperature-, humidity-, and light-controlled room (23 ± 1°C; 50 ± 5% humidity; 12:12 hour light-dark cycle starting at 8:00 AM) and had free access to food and water, except during behavioral experiments. All animals' care and use were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animials and were approved by the Institutional Animal Care and Use Committee of Nagoya University School of Medicine. Animals were treated according to the Guidelines of Experimental Animal Care issued from the Office of the Prime Minister of Japan. The behavioral experimental schedule is shown in Figure 1.

The male C57BL/6- wild-type mice were obtained from Slc Japan (Hamamatsu, Japan). The generation of TNF-α knockout mice, TNF-α-(-/-), was conducted as reported (Taniguchi *et al.* 1997; Nakajima *et al.* 2004). Tumor necrosis factor-α-(-/-) mice were bred locally in the Laboratory Animal Center, University of Nagoya University Graduate School of Medicine in Japan, on the C57BL/6 background. Male C57BL/6- wild-type and C57BL/6-TNF-α-(-/-) mice, 8 to 12 weeks of age, were used in the experiments.

Drug Treatment

Mice were administered TNF-α (1 and 4 μg, intraperitoneal [IP]), Leu-Ile (1.5 and 15 μmol/kg, IP), or vehicle once a day 1 hour before MOR (10 mg/kg, subcutaneous [SC]) treatment for 9 days (Figure 1A). Tumor necrosis factor-α/MOR, Leu-Ile/MOR, or vehicle/MOR indicate coadministration of TNF-α (1 and 4 μg, IP), Leu-Ile (1.5 and 15 μmol/kg, IP), or vehicle and MOR (10 mg/kg, SC). In the withdrawal experiment, mice were administered TNF-α (1 and 4 μg, IP), Leu-Ile (1.5 and 15 μmol/kg, IP), or vehicle without MOR for 5 days after the withdrawal from MOR following 9 successive days of MOR administration (Figure 1B). Morphine/TNF-α/MOR, MOR/Leu-Ile/MOR, or MOR/vehicle/MOR indicate an acute challenge of MOR in mice treated with TNF-α (1 and 4 μg, IP), Leu-Ile (1.5 and 15 μmol/kg, IP), or vehicle for 5 days after the development of MOR-induced sensitization. To determine messenger RNA (mRNA) expression and protein levels, mice were decapitated 2 and 24 hours after the last MOR injection, respectively. In the real-time reverse transcription polymerase chain reaction (RT-PCR) experiment on the antagonism of MOR-induced TNF-α expression, mice were treated with DA D1 receptor antagonist *R* (+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2, 3, 4, 5-tetrahydro-1*H*-3-benzazepine (*R* [+]-SCH23390) (.01 and .1 mg/kg, IP), DA D2 receptor antagonist raclopride (.1 and 1 mg/kg, IP), and the specific opioid receptor antagonist naloxone (NAL) (5 mg/kg, IP) 30, 30, and 15 min before MOR (10 mg/kg, SC) once per day for 9 days, respectively.



Figure 1. Experimental schedules. **(A)** Experimental schedule for the measurement of locomotor activity to investigate effects of TNF-α or Leu-Ile on MOR-induced sensitization. Mice were habituated to apparatus 240 min a day for 3 days and then co-treated with TNF-α or Leu-Ile and MOR for 9 days. Mice were treated with TNF-α (1 and 4 μg, IP) or Leu-Ile (1.5 and 15 μmol/kg, IP) 1 hour before MOR (10 mg/kg, SC). Locomotor activity was measured for 3 hours after the MOR treatment. Open arrows indicate the days when locomotor activity was measured. **(B)** Experimental schedule for the measurement of locomotor activity to investigate the effects of TNF-α or Leu-Ile after the withdrawal from MOR. Mice were treated with TNF-α or Leu-Ile after the development of MOR-induced (10 mg/kg, SC) sensitization: Mice were treated with MOR for 9 days and then with TNF-α (1 and 4 μg, IP) or Leu-Ile (1.5 and 15 μmol/kg, IP) for 5 days without MOR. On day 18, mice were administered only MOR (10 mg/kg, SC), and locomotor activity was measured for 3 hours after the MOR treatment. Open arrows indicate the day when locomotor activity was measured. **(C)** Experimental schedule for the conditioned place preference task to investigate effects of TNF-α or Leu-Ile on MOR-induced place preference. Mice were co-treated with TNF-α or Leu-Ile and MOR in the conditioning period. Mice were treated with TNF-α (1 and 4 μg, IP) or Leu-Ile (1.5 and 15 μmol/kg, IP) 1 hour before MOR (10 mg/kg, SC) or saline. The postconditioning test was carried out 1 day after the conditioning. Closed arrows indicate the days of MOR or saline injection. **(D)** Experimental schedule for the conditioned place preference task to investigate the effects of TNF-α or Leu-Ile after the withdrawal from MOR. Mice were not treated with TNF-α or Leu-Ile in the conditioning period. Mice were treated with TNF-α (1 and 4 μg, IP) or Leu-Ile (1.5 and 15 μmol/kg, IP) for 5 days after withdrawal from MOR. The first postconditioning test was carried out 1 day after conditioning. The second postconditioning test was carried out 5 days after the first postconditioning test. Closed arrows indicate the days of MOR or saline injection. TNF-α, tumor necrosis factor-α; MOR, morphine; IP, intraperitoneal; SC, subcutaneous.

Semiquantative mRNA Analysis by Real-Time RT-PCR

Mice were decapitated 2 hours after the last injection of MOR, and the brains were quickly removed. Various regions including the frontal cortex (Fc), NAc, CPu, and hippocampus (Hip) were rapidly dissected out, frozen, and stored in a deep freezer at −80°C until the assays. Total RNA was isolated using an RNeasy Mini Kit (Qiagen, Hilden, Germany). The levels of TNF-α mRNA were determined by real-time RT-PCR (Bio-Rad Laboratories Inc., Hercules, California) using a TaqMan probe. The 18S ribosomal RNA was used as the internal control (PE Applied Biosystems, Foster, California). Total RNA was converted into complementary DNA (cDNA) using a SuperScript First-Strand System for RT-PCR Kit (Invitrogen Life Technologies, Carlsbad, California) in a total volume of 21 μL (reverse transcriptase [RT]-reaction mixture). Polymerase chain reaction (PCR) was performed using 1 μL of the RT-reaction mixture, 10 nm of each (forward and reverse) primer, 80 nm of TaqMan probe, and 12.5 μL of TaqMan Universal PCR Master Mix (PE Applied Biosystems) in a total reaction volume of 25 μL. The mouse TNF-α primers used were as follows: 5'-CCCTTGCCCAGCCAGAA-3' (forward) and 5'-CCCCCTAAAAGACACGAAGATG-3' (reverse) and TaqMan probe: 5'-AGCTTGATGTCATCTCTTCGTGGGCT-3'. Partial cDNA sequences of mouse TNF-α have been deposited in the National Center for Biotechnology Information (NCBI) GenBank database (accession number: NM_013693). The amplification consisted of an initial step (50°C for 2 min and 95°C for 2 min) and then 40 cycles of denaturation for 15 sec at 95°C and annealing for 1 min at 60°C in an iCycle iQ Detection System (Bio-Rad Laboratories, Inc., Tokyo, Japan). The signal was detected according to the manufacturer's instructions. The expression levels were calculated as described previously (Wada *et al.* 2000).

Immunohistochemical Analysis

For samples for immunohistochemical analysis, mice were killed 24 hours after repeated treatment with Leu-Ile (1.5 μmol/kg, IP) 1 hour before the administration of MOR (10 mg/kg, SC, once a day for 9 days). The brains were sliced at 20 μm in the cryostat. Slices were rinsed briefly with phosphate-buffered saline (PBS) containing .01% Triton X-100 (washing buffer; Sigma-Aldrich, St. Louis, Missouri). They were incubated with primary antibodies in washing buffer overnight at 4°C. After being washed, slices were incubated with secondary antibodies for 2 hours. Polyclonal goat anti-TNF-α antibody (1:100; R&D Systems Ltd., Minneapolis, Minnesota), monoclonal mouse anti-neuron-specific nuclear antigen (NeuN) antibody (1:200; Chemicon, Temecula, California), and monoclonal mouse anti-glial fibrillary acidic protein (GFAP) antibody (1:200; Chemicon International, Inc., Temecula, California) served as primary antibodies. Donkey anti-goat Alexa Fluor 546 (1:1000; Molecular Probes, Inc., Engene, Oregon) and rabbit anti-mouse Alexa Fluor 488 (1:1000; Molecular Probes, Inc.) were used as secondary antibodies for TNF-α immunostaining. Each stained tissue was observed under a fluorescence microscope (Axioskoop 2 plus; Carl Zeiss, Jena, Germany) and analyzed with Axiovision 3.0 systems (Carl Zeiss).

The area with TNF-α-positive cells in the defined NAc region of mice was determined using the software WinROOF (Mitani Co., Ltd., Fukui, Japan) (Kuwahara *et al.* 1999; Tsuji *et al.* 1999). We employed an immunostaining method with which one can analyze the distribution and levels of TNF-α protein in the present investigation, since it is too difficult to use Western blotting or an enzyme immunoassay to quantify the amount of TNF-α protein in brain tissue.

Locomotor Activity

Locomotor activity was measured using an infrared detector (Neuroscience Co., Ltd., Tokyo, Japan) in a plastic box (32 × 22 × 15 cm high). Mice were administered Leu-Ile (1.5 and 15 μmol/kg, IP) or vehicle and habituated for 1 hour in the box. Mice were administered MOR (10 mg/kg, SC) or saline 1 hour after the TNF-α or Leu-Ile treatment, and the locomotor activity was measured for 2 hours immediately after the MOR or saline administration (Figures 1A and 1B). Leu-Ile and MOR were injected once a day for 9 days (days 4–12). In the experiment with withdrawal, mice were administered TNF-α, μ Leu-Ile, or vehicle for 5 days (days 13–17) after the withdrawal from MOR following 9 successive days of MOR administration. On day 18, the mice were administered only MOR (10 mg/kg, SC), and locomotor activity was measured for 2 hours immediately after the administration (Figure 1C).

Conditioned Place Preference

The apparatus used for the place-conditioning task consisted of two compartments: a transparent Plexiglas box and a black Plexiglas box (both 15 × 15 × 15 cm high). To enable mice to distinguish easily the two compartments, the floors of the transparent and black boxes were covered with white plastic mesh and black frosting Plexiglas, respectively. Each box could be divided by a sliding door (10 × 15 cm high). The place-conditioning paradigm was performed by using a previously established procedure with a minor modification (Noda *et al.* 1998; Mizoguchi *et al.* 2004; Niwa *et al*, in press). The experimental schedule for the condition place preference task is shown in Figures 1C and 1D. In the preconditioning test, the sliding door was opened, and the mouse was allowed to move freely between both boxes for 15 min once a day for 3 days. On the third day of the preconditioning test, we measured the time that the mouse spent in the black and transparent boxes by using a Scanet SV-20 LD (Melquest Co., Ltd., Toyama, Japan). The box in which the mouse spent the most time was referred to as the "preferred side," and the other box as the "nonpreferred side." Conditioning was performed during 6 successive days. Mice were given MOR or saline in the apparatus with the sliding door closed. That is, a mouse was subcutaneously given MOR and put in its nonpreferred side for 20 min. On the next day, the mouse was given saline and placed opposite the drug-conditioning site for 20 min. These treatments were repeated for three cycles (6 days). In the postconditioning test, the sliding door was opened, and we measured the time that the mouse spent in the black and transparent boxes for 15 min, using the Scanet SV-20 LD. Place-conditioning behavior was expressed by Post-Pre, which was calculated as: ([postvalue] − [prevalue]), where postvalues and prevalues were the difference in time spent at the drug-conditioning and the saline-conditioning sites in the postconditioning and preconditioning tests, respectively.

In Vivo Microdialysis

Mice were anesthetized with sodium pentobarbital, and a guide cannula (AG-8, EICOM, Kyoto, Japan) was implanted into the NAc (+1.1 mm anteroposterior, +1.0 mm mediolateral from the bregma, and -4.0 mm dorsoventral to the dura) according to the atlas of Franklin and Paxinos (1997) and secured to the skull using stainless steel screws and dental acrylic cement. One day after the operation, a dialysis probe (AI-8-1; 1-mm mem-